Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.4B
58M shares
52-week range
$40.51 – $59.68
4% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
2.9
EV / FCF (TTM)
120
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
www.supernus.comNo one on the platform currently holds SUPN.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,705,222 | $88.1M |
No one on the platform has traded SUPN yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 8.6% | 6.7% | ||||
| Profit Margin % | -5.4% | 4.9% | 16.6% | |||
| Free Cash Flow Margin % | 6.4% | 17.9% | 25.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +7.4% on the P/E track.
At today's price, your expected annual return is +17.7% on the P/E track.
At today's price, your expected annual return is +32.3% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $879M | +25.1% | $2.56 | $2.48–$2.64 | 16.1× | 2 |
| 2027 | $1.4B | +56.0% | $4.46 | $4.37–$4.55 | 9.3× | 2 |
| 2028 | $1.7B | +21.3% | $5.40 | $0.25–$10.55 | 7.6× | 2 |
| 2029 | $1.8B | +10.5% | $5.70 | $4.49–$8.54 | 7.2× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-03 | $0.42 | $0.54 | +27.8% |
| 2026-05-05 | $0.28 | $0.59 | +110.7% |
| 2026-02-24 | $0.28 | $0.92 | +228.6% |
| 2025-11-04 | $0.82 | $1.01 | +23.2% |
| 2025-08-05 | $0.47 | $0.91 | +93.6% |
| 2025-05-06 | $0.38 | $0.42 | +10.5% |
| 2025-02-25 | $0.46 | $0.75 | +63.0% |
| 2024-11-04 | $0.39 |
| $1.06 |
| +171.8% |
| $6.3B |
| — |
| GRALGRAIL Inc. | $75.89 | +0.48% | $3.3B | — |
| HCMHUTCHMED (China) Limited | $13.79 | +0.95% | $2.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$BRK.B $CVX $SUPN $OXY $FSLR Berkshire Hathaway Class B offers diversified exposure, Chevron benefits from disciplined energy production, Supernus advances neurological therapies, Occidental generates strong free cash flow, and First Solar leads U.S. solar manufacturing.
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-8-3-supernus-pharmaceuticals-inc-stock/ $SUPN Supernus Pharmaceuticals Earnings Transcrip
View on StockTwits ↗
$ATKR $FERG $SUPN $INDV $BMY PRE-MARKET MOVERS: Currently Higher: - Atkore (ATKR) up 27.9% after entering into a definitive agreement to be acquired by Prysmian in an all-cash transaction representing an enterprise value of approximately $3.8B - Ferguson (FERG) up 8.2% ahead of its entry into the S&P 500 - Supernus (SUPN) up 14.3% after the company and Indivior entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction - Indivior (INDV) up 1.2% after Supernus and the company entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction - Bristol Myers (BMY) up 3.1% after Financial Times reported AstraZeneca (AZN) is in discussions to combine with the company in a deal valued at nearly $400B Currently Lower After Earnings: - Sportradar (SRAD) down 19.2% - Krystal Biotech (KRYS) down 5.6% - TG Therapeutics (TGTX) down 2.7% - Marriott (MAR) down 2.2% Currently Also Lower: - AstraZeneca (AZN) down 7.1% after Financial Times reported the company is in discussions to combine with Bristol Myers Squibb in a deal valued at nearly $400B - Circle Internet (CRCL) down 5.6% after Morgan Stanley downgraded the stock to Underweight with a price target of $38, down from $106
View on StockTwits ↗
$SUPN: Supernus Pharma (+14.3%) and Indivior Pharmaceuticals $INDV to merge; expected to close in Q4 of 2026.
View on StockTwits ↗
$SUPN (+13.2% pre) Supernus Pharmaceuticals, Indivior Pharmaceuticals to Merge in All-Stock Deal https://ooc.bz/l/109615
View on StockTwits ↗
$SUPN reported 0.53 EPS and 219.06 revenue for Q2. http://www.estimize.com/intro/supn?chart=historical&metric_name=eps&utm_content=SUPN&utm
View on StockTwits ↗
$SUPN and $INDV merge to form a diversified CNS biopharma powerhouse with $2.2B revenue, $125M annual synergies, and greater growth flexibility. https://notreload.xyz/xy/supn-indv-merge-to-form-2-2b-cns-leader/
View on StockTwits ↗
Pre Market Top Gainers PT2 $SXTC $ZBAO $ATKR $SUPN $CABR
View on StockTwits ↗Pre Market Top Gainers PT2 $SXTC $ZBAO $ATKR $SUPN $CABR
View on StockTwits ↗
$SUPN climbed +25% on M&A / acquisition following a Globe Newswire release. Supernus Pharmaceuticals and Indivior Pharmaceuticals agreed to merge in an all-stock transaction creating a diversified CNS biopharmaceutical company with $2.2B in combined revenues and $125M in expected annual cost syn RTPR pushed this release out to users at 6:30:00 AM ET
View on StockTwits ↗
$SUPN Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.